Advertisement
U.S. markets close in 3 hours 30 minutes
  • S&P 500

    5,253.28
    +4.79 (+0.09%)
     
  • Dow 30

    39,783.20
    +23.12 (+0.06%)
     
  • Nasdaq

    16,392.74
    -6.79 (-0.04%)
     
  • Russell 2000

    2,133.84
    +19.49 (+0.92%)
     
  • Crude Oil

    82.63
    +1.28 (+1.57%)
     
  • Gold

    2,236.20
    +23.50 (+1.06%)
     
  • Silver

    24.88
    +0.12 (+0.50%)
     
  • EUR/USD

    1.0806
    -0.0023 (-0.22%)
     
  • 10-Yr Bond

    4.1870
    -0.0090 (-0.21%)
     
  • GBP/USD

    1.2642
    +0.0004 (+0.03%)
     
  • USD/JPY

    151.2950
    +0.0490 (+0.03%)
     
  • Bitcoin USD

    70,884.77
    +1,799.39 (+2.60%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,963.16
    +31.18 (+0.39%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Celgene profit rises 25 pct up on higher cancer drug sales

July 24 (Reuters) - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.

The U.S. biotechnology company's net profit rose to $597.8 million, or 72 cents per share, in the second quarter ended June 30, from $478.1 million, or 56 cents per share, a year earlier.

Excluding special items, it earned 90 cents per share.

Total revenue rose 17 percent to $1.87 billion.

Sales of multiple myeloma treatment Revlimid rose 15 percent to $1.21 billion.

(Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)

Advertisement